Start with your current state.
| Your situation | Options to discuss | Before deciding |
|---|---|---|
| Uncertain diagnosis | Confirm the cause of the patch | Do not select a pigment treatment from appearance alone. |
| New or enlarging patches | Assess activity and consider controlling further loss | Colour return is a separate review question. |
| Stable patches with a wish for colour return | Compare topical, light and selected procedural options | Location and previous response affect expectations. |
| Improvement already achieved | Agree maintenance and monitoring | Clarify how the intensive starting routine changes. |
| Previous limited benefit | Review the adequacy and burden of the trial | Identify what a different option would change. |
This is a map for a clinical conversation, not an automated treatment recommendation. A person may fit several rows at once. Read the relevant option in detail, then discuss eligibility and risks.
Skin medicines are not all the same.
Topical corticosteroids reduce local inflammation and can support colour return. They may suit limited areas, but prolonged or inappropriate use can cause skin thinning, stretch marks or visible vessels.
Tacrolimus and pimecrolimus are calcineurin inhibitors. They are often considered for sensitive sites because they do not thin skin; temporary burning or stinging can occur. Their use for vitiligo is off label in some jurisdictions.
Your written instructions should name the medicine, strength, exact areas, application schedule, planned duration and review date. Instructions for the body are not automatically suitable for eyelids or folds.
Two creams may look similar but serve different roles. Keep their original labels and ask which goes on which area. If directions conflict with what you remember from the appointment, check with the prescriber or pharmacist.
Ask what irritation is expected and what warrants contacting the clinic. More frequent application does not automatically improve a result. Do not extend or restart an old prescription without advice.
Ruxolitinib cream is a targeted option for eligible patients.
Ruxolitinib is a topical JAK inhibitor. The US indication covers non-segmental vitiligo from age 12; treatment is limited to up to 10% body surface area. The EU indication also specifies facial involvement.
In the pivotal studies described by the FDA, about 30% reached at least 75% improvement in a facial score at week 24, versus about 10% using vehicle cream. This is not a guarantee or a measure of total-body clearance.
Response may require more than 24 weeks. The US label uses twice-daily application. The current local label, maximum treated area, other medicines and safety history must be checked.
Before deciding, ask whether your type and extent fit the indication, how much cream the plan requires, what it will cost over time and when the clinician would reassess benefit. Read the safety summary in the updates page before equating “a cream” with “risk free”.
Read the approval and safety context →
FDA: ruxolitinib approval and trial results · EMA: ruxolitinib cream
What actually happens during narrowband UVB?
Narrowband UVB uses a controlled band of ultraviolet light. A clinic calculates and adjusts the exposure; it is not sunbathing or a tanning-bed session. Treatment may cover broader areas or be combined with prescribed skin medicines.
Common schedules involve two or three sessions weekly. A course can extend over 6–12 months, with earlier reassessment. Different guidance uses different response checkpoints, so the service should specify its own review and stopping criteria.
- Before the session: the team checks the skin response, missed sessions and relevant medicine changes. Follow its instructions about products, shielding and eye protection.
- During treatment: exposure is measured and supervised; do not independently add exposure because progress feels slow.
- Between sessions: report painful redness, blistering or other problems to the service.
- At review: compare baseline and follow-up images and discuss whether benefit justifies continued treatment.
Redness, dryness and burning are possible. Home phototherapy requires a prescribed device, training and continued monitoring; it is not simply purchasing a UV lamp. Ask how device servicing, dosing adjustments and access to advice work.
The real commitment includes travel, missed work or school, total sessions and follow-up. Ask about those before purchasing a course.
When might targeted light or surgery enter the discussion?
Excimer light or laser treats selected patches rather than the whole body. It may be useful when localised treatment is practical, but attending repeated sessions and paying per treated area can matter.
Surgery transfers skin or pigment-producing cells. It is generally reserved for selected stable cases. Stability, past treatment and the donor and recipient sites need specialist assessment.
Ask which technique is proposed, why it fits the location, expected healing, scar or colour-mismatch risks, additional treatment and what a limited result would mean. A procedure changes the decision from repeated medicine or light exposure to an intervention with recovery and aftercare.
A clinic should distinguish suitable stable disease from ongoing activity before offering a procedure. A persuasive before-and-after image cannot establish that distinction for you.
International Vitiligo Task Force: treatment recommendations 2023
What are oral treatments intended to do?
For selected rapidly progressive cases, a specialist may discuss a short oral corticosteroid course to suppress activity. This is different from a pigment-restoring plan and carries systemic risks.
Oral JAK inhibition is another pathway. The EMA currently lists upadacitinib for non-segmental vitiligo from age 12 in people who are candidates for systemic therapy. Eligibility, infection risks and monitoring need individual assessment.
A systemic medicine affects the body beyond the treated patches. Expect a discussion of health history, other medicines, pregnancy considerations, relevant screening and laboratory follow-up. An approval for one country or another condition does not establish a vitiligo indication everywhere.
Read the verified upadacitinib update →
International Vitiligo Task Force: treatment recommendations 2023 · EMA: upadacitinib indication and safety
What happens after a response?
Repigmented skin can lose colour again. Maintenance may use a lower-frequency prescribed topical plan or another individual approach.
Before the starting course ends, clarify which areas still need care, the new schedule, review intervals and what to do if new pigment loss appears. Ask for a plan that distinguishes maintaining benefit from restarting intensive treatment.
If benefit has been limited, review the goal, body area, actual use, duration, side effects and practical burden. The choices are not simply “keep going forever” or “give up”. A clinician may advise continuing, changing, combining or ending a treatment trial.
Do not compare treatment success only by how much colour returns. Track whether the outcome you chose at the start has improved and whether the plan remains acceptable.
Check eligibility, access and cost separately.
A treatment can be authorised but not funded, stocked or offered locally. Ask the prescriber and pharmacy which local indication applies, whether prior approval is needed and what documentation supports it.
Before agreeing, compare ongoing supply, consultation, laboratory, travel and session costs. If an option is unavailable, ask about locally appropriate alternatives or a legitimate clinical study rather than buying an unknown formulation online.
OneVitiligo’s Phase 2 objective is to address difficult access through partnerships and new delivery strategies. That service is a future objective; this sample does not yet supply treatments or arrange cross-border care.